Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 531

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 531
---
 that EOC was a customer and identified the license of FYARRO provided to EOC as the sole
performance obligation. The $14.0 million upfront payment received from EOC is non-refundable and non-creditable and is considered fixed consideration. The Company
recognized revenue of $14.0 million in December 2020 when the EOC License Agreement was signed, and the $14.0 million upfront payment was received in January 2021.

F-49

The potential milestone payments and royalty payments under the EOC License Agreement were considered
variable consideration and were constrained with respect to revenue recognition notification from EOC that the milestone and royalty payments had been achieved.

The Company was eligible to receive an additional $257.0 million in the aggregate upon achievement of certain development, regulatory, and sales
milestones, as well as tiered royalties on net sales in the Licensed Territory. Under the terms of the EOC License Agreement, EOC was obligated to fund all research, development, regulatory, marketing and commercialization activities in the defined
Licensed Territory. The Company earned $1.0 million in milestone revenue upon achievement of the FDA approval milestone on November 22, 2021. EOC paid the $1.0 million milestone payment in December 2021. In accordance with the BMS
License Agreement, 20% of the $1.0 million payment, or $0.2 million, was accrued at December 21, 2021, and paid in January 2022.

On
June 27, 2022, the Company received written notice from EOC that EOC elected to terminate the EOC License Agreement, effective immediately, due to alleged material breaches by the Company under such agreement. The Company disputed EOC’s
allegations of material breach. See Note 12 for information regarding the subsequent arbitration between EOC and the Company regarding this dispute.

8. Stockholders’ Equity

Preferred Stock

As of September 30, 2024 and December 31, 2023, under the Company’s certificate of incorporation, as amended and restated, the
Company has 10,000,000 shares of authorized preferred stock, par value $0.0001 per share, with no shares outstanding.

Common Stock and Pre-FundedWarrants

As of September 30, 2024 and December 31, 2023, the Company had 300,000,000 shares
of authorized common stock, par value of $0.000